Monday, August 29, 2016 6:42:39 AM
REUTERS 5:36 AM ET 8/29/2016
Aug 29 (Reuters) - Cynapsus Receives FDA fast track designation for apl
* 130277 for the treatment of off episodes in patients with Parkinson's disease
* Cynapsus receives FDA fast track designation for APL-130277 for the treatment of off episodes in patients with Parkinson's disease
* Says we plan to submit a new drug application (NDA) to FDA in first half of 2017
* Post dose titration phase, top line data for phase 3 efficacy trial CTH-300 is expected in mid-to-late Q4 of 2016
* CTH-201 phase 2 thorough QT study, is expected to commence in Q4 of 2016, and is planned to be completed in first half of 2017 Source text for Eikon: Further company coverage:
(c) Copyright Thomson Reuters 2016. Click For Restrictions - about.reuters.com/fulllegal.asp
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM